The downregulation of Cygb gene expression has been demonstrated in human esophageal cancer, head and neck cancer, lung cancer, ovarian cancer and prostatic cancer via the hyper-methylation of the promoter lesion of the Cygb gene (Shivapurkar et al., 2008; Shaw et al., 2009; Latina et al., 2015). This evidence concerns the gene CYGB and head and neck cancer.